The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Skelid     disodium [(4-chlorophenyl)sulfanyl...

Synonyms: Cl-TMBP, Skelid (TN), CHEMBL1200448, ME-3737, AC1NQL7O, ...
This record was replaced with 60937.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C08141


High impact information on C08141


Chemical compound and disease context of C08141


Biological context of C08141


Anatomical context of C08141


Associations of C08141 with other chemical compounds


Gene context of C08141

  • RESULTS: Tiludronate significantly inhibited both MMP-1 and MMP-3 activity in a concentration-dependent manner [17].
  • The PGF(2alpha)-stimulated phosphorylation of p44/p42 MAP kinase was suppressed by tiludronate [14].
  • However, some agents either lose their efficacy or have no added effects on BMD when they are coadministered (e.g., tiludronate and PTH, calcitonin and PTH, calcitonin and anabolic steroids) [18].
  • Although serum osteocalcin levels were decreased in the medium- and high-dose tiludronate groups, both serum PTH and 1,25(OH)2D levels were increased only in the high-dose group [19].
  • Tiludronate significantly inhibited the NaF-induced IL-6 secretion in human osteoblastic osteosarcoma Saos-2 cells [15].

Analytical, diagnostic and therapeutic context of C08141


  1. Prevention of postmenopausal bone loss by tiludronate. Reginster, J.Y., Lecart, M.P., Deroisy, R., Sarlet, N., Denis, D., Ethgen, D., Collette, J., Franchimont, P. Lancet (1989) [Pubmed]
  2. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study. Reginster, J.Y., Colson, F., Morlock, G., Combe, B., Ethgen, D., Geusens, P. Arthritis Rheum. (1992) [Pubmed]
  3. Effects of tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomy. Murakami, H., Nakamura, T., Tsurukami, H., Abe, M., Barbier, A., Suzuki, K. J. Bone Miner. Res. (1994) [Pubmed]
  4. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Alvarez, L., Peris, P., Guañabens, N., Vidal, S., Ros, I., Pons, F., Filella, X., Monegal, A., Muñoz-Gomez, J., Ballesta, A.M. Arthritis Rheum. (2003) [Pubmed]
  5. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Roux, C., Gennari, C., Farrerons, J., Devogelaer, J.P., Mulder, H., Kruse, H.P., Picot, C., Titeux, L., Reginster, J.Y., Dougados, M. Arthritis Rheum. (1995) [Pubmed]
  6. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines. Vorotnjak, M., Boos, J., Lanvers-Kaminsky, C. Anticancer Drugs (2004) [Pubmed]
  7. Effects of tiludronate on bone loss in paraplegic patients. Chappard, D., Minaire, P., Privat, C., Berard, E., Mendoza-Sarmiento, J., Tournebise, H., Basle, M.F., Audran, M., Rebel, A., Picot, C. J. Bone Miner. Res. (1995) [Pubmed]
  8. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. David, P., Nguyen, H., Barbier, A., Baron, R. J. Bone Miner. Res. (1996) [Pubmed]
  9. Human pharmacokinetics of tiludronate. Sansom, L.N., Necciari, J., Thiercelin, J.F. Bone (1995) [Pubmed]
  10. Tiludronate: bone pharmacology and safety. Bonjour, J.P., Ammann, P., Barbier, A., Caverzasio, J., Rizzoli, R. Bone (1995) [Pubmed]
  11. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Murakami, H., Takahashi, N., Sasaki, T., Udagawa, N., Tanaka, S., Nakamura, I., Zhang, D., Barbier, A., Suda, T. Bone (1995) [Pubmed]
  12. Importance of the paracellular pathway for the transport of a new bisphosphonate using the human CACO-2 monolayers model. Boulenc, X., Marti, E., Joyeux, H., Roques, C., Berger, Y., Fabre, G. Biochem. Pharmacol. (1993) [Pubmed]
  13. Management of Paget's disease of bone. Langston, A.L., Ralston, S.H. Rheumatology (Oxford, England) (2004) [Pubmed]
  14. Tiludronate inhibits prostaglandin F2alpha-induced vascular endothelial growth factor synthesis in osteoblasts. Yoshida, M., Tokuda, H., Ishisaki, A., Kanno, Y., Harada, A., Shimuzu, K., Kozawa, O. Mol. Cell. Endocrinol. (2005) [Pubmed]
  15. Tiludronate inhibits interleukin-6 synthesis in osteoblasts: inhibition of phospholipase D activation in MC3T3-E1 cells. Tokuda, H., Kozawa, O., Harada, A., Uematsu, T. J. Cell. Biochem. (1998) [Pubmed]
  16. Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Mönkkönen, J., Similä, J., Rogers, M.J. Life Sci. (1998) [Pubmed]
  17. Effects of bisphosphonate on matrix metalloproteinase enzymes in human periodontal ligament cells. Nakaya, H., Osawa, G., Iwasaki, N., Cochran, D.L., Kamoi, K., Oates, T.W. J. Periodontol. (2000) [Pubmed]
  18. Prevention and treatment of osteoporosis: efficacy of combination of hormone replacement therapy with other antiresorptive agents. Wimalawansa, S.J. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry. (2000) [Pubmed]
  19. Bisphosphonate tiludronate increases bone strength by improving mass and structure in established osteopenia after ovariectomy in rats. Ohnishi, H., Nakamura, T., Narusawa, K., Murakami, H., Abe, M., Barbier, A., Suzuki, K. Bone (1997) [Pubmed]
  20. Effect of ovariectomy on intraosseous vascularization and bone remodelling in rats: action of tiludronate. Laroche, M., Barbier, A., Ludot, I., Vernhet, C., Thiechart, M., Viguier, G., Mazieres, B. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. (1996) [Pubmed]
  21. Bisphosphonate effects in rat unloaded hindlimb bone loss model: three-dimensional microcomputed tomographic, histomorphometric, and densitometric analyses. Barou, O., Lafage-Proust, M.H., Martel, C., Thomas, T., Tirode, F., Laroche, N., Barbier, A., Alexandre, C., Vico, L. J. Pharmacol. Exp. Ther. (1999) [Pubmed]
  22. The methodology of clinical trials of oral tiludronate in Paget's disease of bone. Roux, C. Bone (1995) [Pubmed]
  23. Biological and radiological responses to oral etidronate and tiludronate in Paget's disease of bone. Devogelaer, J.P., Malghem, J., Stasse, P., Nagant de Deuxchaisnes, C. Bone (1997) [Pubmed]
WikiGenes - Universities